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Edited by Felix WielandAbstract a-Glucosidase (EC 3.2.1.3) is a lysosomal enzyme that
hydrolyses a-1,4- and a-1,6-linkages of glycogen to produce free
glucose. A deﬁciency in a-glucosidase activity results in glycogen
storage disorder type II (GSD II), also called Pompe disease.
Here, D-glucose was shown to be a competitive inhibitor of a-glu-
cosidase and when added to culture medium at 6.0 g/L increased
the production of this protein by CHO-K1 expression cells and
stabilised the enzyme activity. D-Glucose also prevented a-gluco-
sidase aggregation/precipitation and increased protein yield in a
modiﬁed puriﬁcation scheme. In ﬁbroblast cells, from adult-onset
GSD II patients, D-glucose increased the residual level of a-glu-
cosidase activity, suggesting that a structural analogue of D-glu-
cose may be used for enzyme enhancement therapy.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lysosomal a-glucosidase (EC 3.2.1.3) is responsible for
hydrolysing a-1,4- and a-1,6-linkages of glycogen, releasing
free glucose [1]. A deﬁciency in lysosomal a-glucosidase results
in glycogen storage disorder type II (GSD II, also known as
Pompe disease or acid maltase deﬁciency) [2]. This reduction
or loss of a-glucosidase activity results in the lysosomal accu-
mulation of glycogen in various cell types, with myocytes of
cardiac, respiratory and skeletal muscles most severely aﬀected
[3]. GSD II patients present within a spectrum of clinical phe-
notypes, ranging from the severe, rapidly progressive infantile-
onset form with cardiac involvement, to a less progressive
adult-onset form without cardiac symptoms. The clinical phe-
notype of GSD II is thought to be primarily determined by the
nature of the variant alleles and the amount of residual enzyme
activity [4]. Infantile-onset GSD II patients tend to have little
or no detectable a-glucosidase activity, while the residual
a-glucosidase activity in adult-onset patients is between 7%
and 22% of normal controls [5,6].
Enzyme replacement therapy (ERT) using recombinant hu-
man a-glucosidase has been evaluated for the treatment of
GSD II in human clinical trials [7–10]. Large quantities of a-glu-*Corresponding author. Fax: +61 8 8161 7100.
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doi:10.1016/j.febslet.2006.06.096cosidase (up to 40 mg/kg) were required for this ERT to be eﬀec-
tive in GSD II patients [7–10]. The need for such high amounts
of recombinant human a-glucosidase has necessitated eﬃcient
overexpression systems [11,12] and led to a number of methods
for enzyme puriﬁcation to improve yields [13]. However, prob-
lems have been encountered with a-glucosidase aggregation and
precipitation during puriﬁcation [13] (www.worldpompe.org./
synpac.html).
The inability to completely clear lysosomal glycogen storage
in ERT-treated GSD II patients, despite high doses of a-gluco-
sidase, has stimulated interest in alternative therapies. Another
potential approach to treatGSDII is enzyme enhancement ther-
apy (EET, or chemical chaperone therapy), which has recently
been investigated for other LSD (Gaucher disease/b-glucosidase
[14], MPS IVB/b-galactosidase [15]; Fabry disease/a-galactosi-
dase A [16,17]; Tay-Sachs and Sandhoﬀ diseases/b-hexosamini-
dase [18]). This therapy is based on the ability of chemical
reagents/active site inhibitors to stabilise the variant protein in
patient cells [19]. Protein stabilisers are thought to assist the
folding of variant protein within the rough endoplasmic reticu-
lum, increasing the amount of protein that passes the quality
control process, thereby enhancing the residual enzyme activity
in aﬀected cells. EET could be used to stabilise themis-sense var-
iant a-glucosidase in GSD II patients, particularly in adult-
onset patients who have signiﬁcant residual enzyme activity.
This therapy would aim to shift the dynamic balance between
the residual enzyme activity and substrate turnover in the
patient [20], to reduce the level of substrate accumulation below
the critical threshold and avoid the onset of pathogenesis.
D-Glucose is the product of a-glucosidase glycogen hydroly-
sis and is an inhibitor of the enzyme. It was hypothesised that
D-glucose could interact with the a-glucosidase catalytic site to
improve the stability of both normal and mis-sense variant
a-glucosidase protein. In this study we have investigated the
ability of D-glucose to increase a-glucosidase production in
CHO-K1 expression cells, to improve puriﬁcation yields of
the recombinant protein from culture medium and to increase
the amount of a-glucosidase in adult-onset GSD II patient
ﬁbroblasts.2. Materials and methods
2.1. Materials
Non-protein binding microtitre plates (96-well, ﬂat bottom) were
purchased from Interpath Services (Sydney, NSW, Australia). Bovine
serum albumin (BSA) was obtained from Sigma (St. Louis, MO,
USA). The polyclonal antibody to a-glucosidase was raised againstblished by Elsevier B.V. All rights reserved.
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Fig. 1. The eﬀect of D-glucose on a-glucosidase activity in culture
medium from CHO-K1 expression cells. CHO-K1 cells expressing a-
glucosidase were cultured in either a-MEM (s, 1.0 g/L D-glucose), or
in a-MEM supplemented with a ﬁnal concentration of either 3.1 g/L
(n), or 4.0 g/L (m) or 6.0 g/L (d) of D-glucose. CHO-K1 cells were
cultured in the latter conditions for up to 144 h (n = 6 per treatment
group). The results showed a signiﬁcant diﬀerence for the a-MEM
versus glucose supplemented treatment groups at 54, 72 and 98 h time
points (P < 0.001, t-test). The 6.0 g/L treatment showed a signiﬁcant
diﬀerence from the 3.1 g/L treatment at 98 h (P < 0.001, t-test) and the
4.0 g/L treatment at 144 h (P < 0.001, t-test). The total cell protein for
the CHO-K1 cell extracts was 5.0 ± 0.3 mg/mL.
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scribed [21]. The a-glucosidase, a-L-iduronidase and 4-sulphatase
CHO-K1 expression cell lines were as previously described [11,22,23].
Anhydrous D-glucose, anhydrous D-galactose and sucrose were from
Ajax Chemicals (Auburn, NSW, Australia). a-MEM was purchased
from Gibco BRL Life Technologies Inc (Grand Island, NY, USA),
and BME from ICN Biochemicals Inc. (Aurora, OH, USA). Foetal
calf serum and trypsin-versene were purchased from JRH Biosciences
(Lenexa, KS, USA). Sephadex-G100 beads for gel ﬁltration were pur-
chased from Sigma and pre-swollen concanavalin A–Sepharose was
purchased from Amersham Pharmacia Biotechnology (Uppsala, Swe-
den). Ultraﬁltration membranes YM10 were purchased from Millipore
Corporation (Bedford, MA, USA). All other reagents were purchased
from Sigma.
2.2. Determination of enzyme activities
a-Glucosidase, a-L-iduronidase and 4-sulphatase activities were
measured using the ﬂuorogenic substrates 4-methylumbelliferyl a-D-
glucoside, 4-methylumbelliferyl-iduronide and 4-methylumbelliferyl
sulphate, as previously described [24–26]. Kinetic experiments with
the ﬂuorogenic substrates used 0–5 mM of either 4-methylumbelliferyl
a-D-glucoside or 4-methylumbelliferyl-iduronide, in the presence of
either 0, 6, 25 or 50 g/L D-glucose (0, 33, 139, 278 mM). Linewe-
aver–Burk plots for both a-glucosidase and a-L-iduronidase were used
to determine the Michaelis–Menten constant (Km) and maximum
velocity of catalysis (Vmax) for each condition. The inhibitory constant
(Ki) value was calculated from plots of slope (from the Lineweaver–
Burk plots) versus D-glucose inhibitor concentration.
2.3. a-Glucosidase puriﬁcation
Puriﬁcation of precursor a-glucosidase from culture medium was
conducted as previously described for human urine [27] and adapted
for CHO-K1 culture medium [11]. For the modiﬁed procedure devel-
oped here, an equal volume of 50 mM sodium acetate, 20 mM sodium
phosphate, 1 M NaCl, pH 5.2 (A-P buﬀer, as described in [13]) was
added to clariﬁed tissue culture medium to stabilise the a-glucosidase
activity. This was loaded (2 L) onto a 10 mL concanavalin A–Sephar-
ose column and run under gravity at 4 C. The column was washed
with 50 mL of A-P buﬀer and eluted with 15 mL of the same buﬀer
containing 1 M methyl-a-D-glucopyranoside. Elution was maximised
by circulating this eluate over the column three times and then rinsing
the column with 5 mL of fresh elution buﬀer. The concanavalin-A elu-
ate was adjusted to 125 g/L D-glucose and 0.1% (v/v) Tween 20 then
concentrated with a YM10 membrane that had been pre-soaked in
0.1% (v/v) Tween 20 in distilled water. The concentrated eluate was ap-
plied to a Sephadex G-100 column (50 · 1.5 cm) in running buﬀer
(20 mM sodium acetate, pH 4.6, containing 25 mM NaCl). The eluate
was assayed for a-glucosidase and the active fractions pooled and con-
centrated ﬁve-fold. The concentrated eluate was dialysed against PBS
and ﬁltered through a MILLEX-GV 0.22 lm sterile ﬁlter unit that
had been pre-soaked in 0.1% (w/v) Tween 20 in distilled water and as-
sayed for protein by the Lowry method [28].
2.4. Determination of a-glucosidase protein in GSD II patient skin
ﬁbroblasts
Conﬂuent skin ﬁbroblast cells were treated either with (6 g/L) or
without D-glucose for three days then harvested and cell lysates pre-
pared by sonication. Cell lysates were evaluated for a-glucosidase pro-
tein using a Luminex bead system (BioRad, USA). Wells of a 96-well
microtitre ﬁlter plate were pre-wet with 100 lL of assay buﬀer (0.05%
(v/v) Tween 20, 0.5% (w/v) BSA, 0.05% (w/v) c-globulin in 0.01 M
NaH2PO4/NaOH, pH 7.4, with 138 mM NaCl plus 0.05% (w/v) so-
dium azide) and the buﬀer was then suctioned oﬀ before the addition
of 50 lL a-glucosidase polyclonal antibody-coupled beads (5000
beads, coupled according to the manufacturer’s instructions; BioRad,
USA), to each well. The buﬀer was suctioned oﬀ and then either a-glu-
cosidase standards serially diluted in assay buﬀer were added (0–
1000 pg in 100 lL, assayed in duplicate) or 100 lL of assay buﬀer
added as blanks or GSD II patient skin ﬁbroblast cell lysates (2 lL
in 100 lL of assay buﬀer) added to the microtitre wells. The a-glucosi-
dase reporter antibody (biotinylated: Biotinylation of antibodies was
performed with a FluoReporterBiotin-XX Labeling Kit according
to the manufacturer’s instructions; Molecular Probes Inc. Eugene,
OR, USA) was diluted in assay buﬀer (320 lg/L) and 50 lL added toeach well. The plates were then covered in foil and shaken at room
temperature (150 rpm for 1 h on the Thermoline Orbital Shaker;
Thermoline Scientiﬁc Equipment Pty. Ltd, Australia) and then incu-
bated overnight at 4 C. Wells were allowed to reach room tempera-
ture by shaking at 150 rpm for 1 h and then washed three times with
100 lL of wash buﬀer (0.01 M NaH2PO4/NaOH, pH 7.4, with
138 mM NaCl, containing 0.05% (w/v) Tween 20). The buﬀer was suc-
tioned oﬀ and 125 lL of streptavidin phycoerythrin (1.2 mg/L in assay
buﬀer) was added at 50 ng/well (400 lg/L), then the plate sealed and
shaken at 150 rpm for 10 min at room temperature. The plate was
uncovered and ﬂuorescence measured on a Bio-Plex array system
(Bio-Rad, USA). All results were interpolated through a standard
curve to calculate the concentration of a-glucosidase.
2.4.1. GSD II patients. Infantile-onset (n = 6) and adult-onset
(n = 4) GSD II patient skin ﬁbroblasts were from patient referrals to
the National Referral Laboratory for Lysosomal, Peroxisomal and Re-
lated Genetic Disorders, within the Department of Genetic Medicine,
Children Youth and Women’s Health Service, Adelaide, Australia.
The unaﬀected control ﬁbroblasts were from healthy human donors.
All ﬁbroblast samples were de-identiﬁed in accordance with human
ethics approval and administered by an independent operator (Dr. Mi-
chael Fietz, Head of the National Referral Laboratory).3. Results
3.1. The eﬀect of D-glucose concentration on a-glucosidase
expression in CHO-K1 cells
The expression of a-glucosidase in a-MEM (1.0 g/L D-glu-
cose) resulted in an initial increase in a-glucosidase activity
in the culture medium for up to 24 h of culture, but this was
followed by a progressive loss of activity for additional culture
time points (Fig. 1). The addition of extra D-glucose to a-
MEM (3.1, 4.0 and 6.0 g/L ﬁnal concentrations) resulted in a
concentration-dependent increase in a-glucosidase activity
over a 72 h time course. Following the 72 h time point, a pla-
teau in a-glucosidase activity was observed for the 3.1 g/L D-
glucose treated culture. However, the 4.0 and 6.0 g/L D-glucose
treated cultures continued to increase in a-glucosidase activity
for up to 144 h. The increase in a-glucosidase activity in these
culture media was associated with a similar increase in the
R. Kakavanos et al. / FEBS Letters 580 (2006) 4365–4370 4367amount of a-glucosidase protein, with mainly precursor a-
glucosidase and minor amounts of mature form, evident by
immune detection (data not shown).
3.2. Eﬀect of sugar and butyric acid on a-glucosidase, a-L-
iduronidase and 4-sulphatase expression in CHO-K1 cells
The speciﬁcity of the eﬀect of D-glucose on a-glucosidase
production was examined using either diﬀerent saccharides
or energy sources and compared to other expression systems.
D-Glucose, D-galactose (another monosaccharide), sucrose (a
disaccharide) and butyric acid (a non-sugar energy source)
were investigated for their eﬀect on CHO-K1 cells expressing
either a-glucosidase, a-L-iduronidase or 4-sulphatase (Fig. 2).
For a-glucosidase, all of the treatment groups showed an in-
crease in enzyme activity in each culture medium for up to
72 h of culture (Fig. 2A). However, the amount of a-glucosi-
dase activity was higher with D-glucose (6.0 g/L) and D-galac-0
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Fig. 2. The eﬀect of either diﬀerent saccharides or energy sources on
lysosomal enzyme expression in CHO-K1 cells. CHO-K1 cells
expressing either a-glucosidase (A) a-L-iduronidase (B) and 4-sulpha-
tase (C) were cultured in either a-MEM (s) or a-MEM containing
either 6.0 g/L of D-glucose (d), 6.0 g/L D-galactose (m), 6.0 g/L
sucrose (n) or 0.1 M butyric acid (h). CHO-K1 cells were cultured in
the latter conditions for up to 168 h (n = 3 per treatment group). All
points where error bars showed no overlap were signiﬁcantly diﬀerent
(P < 0.001, t-test). The total cell protein for the CHO-K1 cell extracts
was 4.4 ± 0.3 mg/mL. The apparently lower a-glucosidase expression
in the ﬁgure compared to Fig. 1 was due to a lower number of
expression cells as indicated by the total protein in the cell extracts.tose (6.0 g/L) suggesting an increase in production (synthesis/
secretion into the medium) for these two treatment groups.
Following this time point only the cultures treated with either
D-glucose (6.0 g/L) or D-galactose (6.0 g/L) showed an increase
in a-glucosidase activity, whereas the other treatment groups
showed a progressive decline in a-glucosidase activity. The re-
duced activity in the a-MEM, sucrose and butyric acid-treated
CHO-K1 cultures indicated a problem with a-glucosidase sta-
bility, but this was less evident in the culture treated with D-
galactose (6.0 g/L) and not evident in the culture treated with
D-glucose (6.0 g/L; Fig. 2A).
The eﬀect of D-glucose and D-galactose on the amount of a-
glucosidase produced by CHO-K1 expression cells (Fig. 2A)
was not observed for CHO-K1 cells expressing a-L-iduroni-
dase (Fig. 2B). Instead, the addition of either D-glucose, D-
galactose or sucrose resulted in a lower amount of a-L-iduron-
idase activity when compared to the control medium (Fig. 2B).
Butyric acid resulted in an increase in the level of a-L-iduron-
idase but this was not stable after 72 h and showed a decline of
a-L-iduronidase comparable to control medium. However,
there was a sugar-dependent eﬀect on a-L-iduronidase stability
in long-term 168 h cultures, with 6.0 g/L D-glucose then 6.0 g/L
D-galactose having the most eﬀect (Fig. 2B). The stability eﬀect
observed for 6.0 g/L D-glucose and 6.0 g/L D-galactose on both
a-glucosidase (Fig. 2A) and a-L-iduronidase (Fig. 2B) was not
evident for 4-sulphatase (Fig. 2C), despite a slight increase in
the production of 4-sulphatase with either D-glucose, or D-
galactose or sucrose addition (Fig. 2C). This slight increase
in 4-sulphatase production with sugar addition was less than
that observed for butyric acid.3.3. Enzyme kinetic analysis of a-glucosidase and a-L-
iduronidase
Inhibition experiments showed that D-glucose was a rela-
tively weak inhibitor of a-glucosidase (Ki = 44 mM, Fig. 3A).
Lineweaver–Burk plots showed that the Km and Vmax values
for recombinant a-glucosidase (puriﬁed a-glucosidase from
CHO-K1 culture medium) were 2.4 mM and 5 nmol/min,
respectively, with the 4-methylumbelliferyl a-glucoside sub-
strate (Fig. 3B). In the presence of D-glucose, the Km for a-glu-
cosidase increased in proportion to the concentration of
D-glucose, but the Vmax remained constant. This indicated that
D-glucose was acting as a competitive inhibitor of a-glucosidase
(Fig. 3B). The inhibitory constant (Ki) value was calculated as
45 mM from plots of slope versus D-glucose inhibitor concen-
tration (from the Lineweaver–Burk plots, data not shown).
The Vmax (47.6 nmol/min) and Km (0.14 mM) values for
a-L-iduronidase (using the 4-methylumbelliferyl-iduronide sub-
strate) were both altered by the addition of D-glucose, indicat-
ing that it was acting as an uncompetitive inhibitor (Fig. 3C).3.4. Improved yield of recombinant a-glucosidase from CHO-K1
cell cultures with D-glucose
Puriﬁcation of a-glucosidase from CHO-K1 cell culture
using a previously reported method [11] resulted in a visible
precipitate during concentration and gel ﬁltration, leading to
puriﬁcation yields of around 10% (Table 1A). The addition
of 128 mg/mL of D-glucose (almost completely inhibiting a-
glucosidase, Fig. 3) to the concanavalin A column eluate, prior
to concentration and loading onto the Sephadex G-100 gel ﬁl-
tration column, resulted in the elimination of the previously
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Fig. 3. Kinetics analysis of a-glucosidase and a-L-iduronidase in the
presence of D-glucose. a-Glucosidase enzyme inhibition curve for D-
glucose (n = 3, A) and Lineweaver–Burk plots of a-glucosidase (B) and
a-L-iduronidase (C) in the presence of the inhibitor D-glucose at
concentrations of either 0 (s), 6.0 (d), 25 (m) or 50 (n) g/L. The Ki for
the D-glucose inhibition of a-glucosidase was 44 mM from the
inhibition curve and 45 mM from the Lineweaver–Burk plots.
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were also improved by using A-P buﬀer in the culture medium
(Table 1B), as previously reported by Van Hove and colleagues
[13]. Recirculation of the methyl-glucopyranoside elution buf-
fer over the concanavalin A column increased a-glucosidase
recovery from the column. The modiﬁed puriﬁcation protocol
resulted in a 3.5-fold increase in ﬁnal yield when compared to
the previously reported method (Table 1). Immune analysis of
puriﬁed a-glucosidase indicated the presence of predominantly
precursor a-glucosidase (110 kDa) with minor quantities of the
95 and 76 kDa mature forms (data not shown).3.5. Eﬀect of D-glucose on a-glucosidase activity in GSD II
patient skin ﬁbroblasts
Either BME or BME supplemented with D-glucose (6.0 g/L)
was added to conﬂuent GSD II skin ﬁbroblasts and incubatedfor 72 h. An increase in the amount of a-glucosidase protein
was observed for normal control and adult-onset GSD II pa-
tient skin ﬁbroblasts treated with 6.0 g/L D-glucose (Fig. 4),
when compared to the control BME medium. The increase
in a-glucosidase protein corresponded to a similar increase in
a-glucosidase activity (data not shown). In contrast, only
two of the six infantile-onset GSD II patient cell lines showed
a detectable increase in a-glucosidase protein with D-glucose
treatment (Fig. 4), but this protein had no detectable activity.
In all of the ﬁbroblasts tested (GSD II and normal control),
four other lysosomal markers b-glucuronidase, Saposin C,
Lamp 1 and iduronate-2-sulphatase showed either no change
or a slight reduction in protein after D-glucose treatment (data
not shown).4. Discussion
Eﬀective ERT in GSD II patients requires extremely large
doses of recombinant a-glucosidase [7–10]. The puriﬁcation
of recombinant human a-glucosidase from CHO-K1 cell cul-
ture medium has addressed this need, but there have been
problems with aggregation and precipitation of the puriﬁed
protein [13] (www.worldpompe.org./synpac.html). This led to
the investigation of a strategy to stabilise the a-glucosidase cat-
alytic site using substrate product, with the aim of increasing
the yield of a-glucosidase protein from expression cells and
in an improved puriﬁcation scheme.
D-Glucose is the product of a-glucosidase hydrolysis and
was shown to be a competitive inhibitor, which speciﬁcally
interacted with the catalytic site of a-glucosidase. D-Glucose
at a concentration of 6.0 g/L (33 mM) was able to dramatically
increase the production (synthesis/secretion) of a-glucosidase
in CHO-K1 expression medium. The concentration of D-glu-
cose, at which this biological eﬀect was observed, was similar
to the Ki for a-glucosidase (45 mM), consistent with the D-glu-
cose eﬀect being mediated by binding to the active site of a-glu-
cosidase. In the presence of 6.0 g/L D-glucose or D-galactose,
a-glucosidase activity in the culture medium from CHO-K1
cells was maintained for more than 72 h after the initial treat-
ment; but in the absence of these monosaccharides, a progres-
sive drop in a-glucosidase activity was observed following this
time point. The increased production of a-glucosidase in the
presence of these monosaccharides suggested that either they
provided a better energy source for protein expression or
possibly improved the folding/yield of a-glucosidase in the
biosynthetic compartment. However, preventing the loss of
a-glucosidase activity for cultures that were extended past
72 h, indicated a stability eﬀect and this was most evident for
D-glucose treatment. The D-glucose stability eﬀect was not
observed for 4-sulphatase, and only partially evident for
another glycosidase a-L-iduronidase.
A previous study reported increased production and stabili-
sation of a-glucosidase in the presence of D-glucose and buty-
rate [12], which was explained by a decrease in pH of culture
conditions resulting from the increase in lactic acid produc-
tion. Here, this stabilisation of a-glucosidase was shown to
be most likely due to D-glucose rather than butyrate. D-Glu-
cose also prevented aggregation and precipitation of a-glucosi-
dase during puriﬁcation from CHO-K1 cell culture medium
and improved the yield compared to a previously described
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Fig. 4. a-Glucosidase protein levels in GSD II patient skin ﬁbroblasts
treated with D-glucose. The eﬀect of D-glucose on a-glucosidase
protein levels of normal control (d) and GSD II patient skin ﬁbroblast
cell lines from either infantile-onset patients with negligible levels of a-
glucosidase protein (m), infantile-onset patients with variant a-
glucosidase protein (n), or adult-onset patients (n). Fibroblast cell
lines were cultured either in the presence or absence of D-glucose (6 g/
L) for 72 h before determining the level of a-glucosidase protein. The
age of the adult-onset patients was similar to the normal controls.
After D-glucose treatment, the a-glucosidase activity increased from
101 to 120 nmol/h/mg in the normal control and from 21.8 ± 8.0 to
29.8 ± 9.0 nmol/h/mg in the adult-onset GSD II patient cells, showing
the same trend as observed for the a-glucosidase protein values. The
infantile-onset GSD II patients had little or no a-glucosidase enzyme
activity and this did not change after D-glucose treatment.
Table 1
Puriﬁcation of a-glucosidase
Sample Activity (nmol/min/ml) a-Glucosidase (lg/ml) Volume (ml) Total a-glucosidase (lg) Yield (%)
A
Media 51.04 85.07 55.00 4678.85 100.00
Con A ﬂowthrough 6.50 10.83 54.00 584.98 12.50
Concentrated eluate 450.00 750.00 3.00 2250.00 48.10
Sephadex eluate 29.85 49.75 18 895.50 19.10
Concentrated eluate 98.20 163.67 2.80 458.28 9.80
B
Media 6.69 11.20 1000.00 11200.00 100.00
Media + AP buﬀer 4.50 7.60 2000.00 15200.00 137.70
Con A ﬂowthrough 0.17 0.28 1970.00 551.60 4.90
Recirculated Con A eluate 319.90 533.20 9.50 5065.40 45.20
Con A eluate + glucose 225.90 376.40 10.00 5332.00 47.60
Concentrated eluate 1050.90 1751.66 2.00 3503.32 31.20
Sephadex eluate 82.50 138.00 30.00 4140.00 36.90
Concentrated eluate 704.30 1173.80 3.50 4108.30 36.70
Sample A shows the puriﬁcation of CHO-K1 a-glucosidase medium using a previously described method [11]. Sample B shows CHO-K1 a-
glucosidase medium puriﬁcation with a modiﬁed method as described in Section 2. Con A = concanavalin A–Sepharose column.
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glucosidase, with D-glucose, could substantially reduce the cost
of a-glucosidase preparation for ERT.
The ability of D-glucose to stabilise endogenous a-glucosi-
dase in CHO-K1 cells suggested that a similar strategy could
be used to enhance the level of a-glucosidase activity in GSD
II cells. In ﬁbroblasts from GSD II patients, only those with
signiﬁcant levels of a-glucosidase protein responded to D-glu-
cose treatment. D-glucose treatment of GSD II skin ﬁbroblasts
from adult-onset patients resulted in an increase in residual a-
glucosidase protein and activity, providing proof-of-principle
for the use of a D-glucose analogue in EET. EET has already
shown promising results in preclinical trials of four other LSD:
Gaucher [14], mucopolysaccharidosis IVB [15], Fabry [16,17]
and Tay-Sachs/Sandhoﬀ patients [18]. Infusion of D-galactose
in a 55-year old Fabry patient (deﬁcient in a-galactosidase) in-
creased residual activity of the enzyme 1.4-fold (from 7% to
10% of normal values) in lymphocytes and this was suﬃcient
to signiﬁcantly ameliorate the patient’s condition [29]. Here,
the treatment of adult-onset GSD II skin ﬁbroblasts with D-
glucose resulted in a 1.5-fold increase in residual a-glucosidase
activity consistent with the results in the Fabry patient. How-
ever, D-glucose was only a low aﬃnity inhibitor of a-glucosi-
dase (Ki = 45 mM) and high level glucose infusion would not
be an appropriate therapy for patients, due to the impact on
glucose metabolism. Analogues of D-glucose that are more po-
tent and speciﬁc inhibitors of a-glucosidase may provide can-
didate compounds for EET in GSD II patients, who have
residual enzyme activity.
This study demonstrated that D-glucose stabilised a-glucosi-
dase, allowing increased expression and improved puriﬁcation
of the recombinant protein. D-Glucose enhanced the residual
a-glucosidase protein and activity in adult-onset GSD II pa-
tient cells, providing proof-of-principle for EET in patients
with mis-sense mutations (56 of the 109 mutations detected
in the GAA gene: http://www.hgmd.cf.ac.uk/).Acknowledgements: This work was funded by NH&MRC Program
and Fellowship Grant funding, a University of Adelaide Postgraduate
Scholarship and an M.S. McLeod Award.
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